Tradjenta

Tradjenta is a brand name of linagliptin, approved by the FDA in the following formulation(s):

TRADJENTA (linagliptin - tablet; oral)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: May 2, 2011
  
  Strength(s): 5MG ^[RLD]

Has a generic version of Tradjenta been approved?

No. There is currently no therapeutically equivalent version of Tradjenta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tradjenta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
  Patent 6,303,661
  Issued: October 16, 2001
  Inventor(s): Demuth; Hans-Ulrich & Rosche; Fred & Schmidt; Joem & Pauly; Robert P. & McIntosh; Christopher H. S. & Pederson; Ray A.
  Assignee(s): Probiodrug
  Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
  
  Patent expiration dates:
  
  
  • April 24, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR
  
  



• 
  Method of regulating glucose metabolism, and reagents related thereto
  Patent 6,890,898
  Issued: May 10, 2005
  Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
  Assignee(s): Trustees of Tufts College
  1149336 Ontario Inc.
  New England Medical Center Hospitals, Inc.
  The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
  
  Patent expiration dates:
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
  
  



• 
  Method of regulating glucose metabolism, and reagents related thereto
  Patent 7,078,381
  Issued: July 18, 2006
  Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
  Assignee(s): Trustees of Tufts College
  The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.
  
  Patent expiration dates:
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
  
  



• 
  8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
  Patent 7,407,955
  Issued: August 5, 2008
  Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf R. H. & Tadayyon; Mohammad
  Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG
  The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
  
  Patent expiration dates:
  
  
  • August 12, 2023
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Method of regulating glucose metabolism, and reagents related thereto
  Patent 7,459,428
  Issued: December 2, 2008
  Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
  Assignee(s): Trustees of Tufts College
  New England Medical Center Hospitals, Inc.
  1149336 Ontario, Inc.
  One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.
  
  Patent expiration dates:
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 2, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Tradjenta Consumer Information (Drugs.com)
• Tradjenta Consumer Information (Wolters Kluwer)
• Tradjenta Consumer Information (Cerner Multum)
• Tradjenta Advanced Consumer Information (Micromedex)
• Linagliptin Consumer Information (Wolters Kluwer)
• Linagliptin Consumer Information (Cerner Multum)
• Linagliptin Advanced Consumer Information (Micromedex)